Pacific Edge Limited, a cancer diagnostics company, engages in development and commercialization of bladder cancer diagnostic and prognostic tests for patients. It operates through two segments, Commercial and Research. The company offers Cxbladder, a genomic urine biomarker test for the stratification and surveillance of bladder cancer. It also develops Cxbladder Triage, a frontline diagnostic product that helps de-intensify clinical work-up in microhematuria patients; Cxbladder Detect, which improve practice workflow and efficiency in urological care; Cxbladder Triage Plus, a non-invasive surveillance alternative that can reduce the burden of repeated cystoscopy in patients; and Cxbladder Monitor, a non-invasive surveillance alternative that reduces the burden of repeated cystoscopy in patients with a recurrent non-muscle invasive bladder cancer. In addition, the company is developing products for bladder, gastric, colorectal and endometrial cancers, and melanoma. Pacific Edge Limited was incorporated in 2001 and is headquartered in Dunedin, New Zealand.
Frequently asked questions
What sector does Pacific Edge Limited (PEB) operate in?
Pacific Edge Limited belongs to the Healthcare sector and operates in the Diagnostics & Research industry.
What is Pacific Edge Limited (PEB) current stock price?
As of the latest data, Pacific Edge Limited stock price is NZ$0.26, with a previous close of NZ$0.27. Pacific Edge Limited lost -NZ$0.01 in the last trading session, representing a -1.89% loss.
What is Pacific Edge Limited (PEB) current market capitalization?
Pacific Edge Limited market cap is approximately 322.88 million.
What is Pacific Edge Limited (PEB) Earnings Per Share (EPS)?
The trailing EPS is -NZ$0.04, and the forward EPS is -NZ$0.02.
Does Pacific Edge Limited (PEB) pay dividends?
No. Pacific Edge Limited does not pay a dividend.
What is Pacific Edge Limited (PEB) beta (volatility) score?
Pacific Edge Limited has a beta of 0.820, meaning its volatility is roughly in line with the market.
